Barr/AstraZeneca tamoxifen antitrust suit dismissed
Executive Summary
AstraZeneca and Barr "authorized generic" agreement for breast cancer agent Nolvadex did not violate antitrust laws, Brooklyn, N.Y. federal judge rules. Complaints from consumers and third-party payors argued that 1993 agreement under which Barr marketed generic tamoxifen until August 2002 kept other generics off market. Judge's ruling dismisses all state and federal claims. A prior Justice Department investigation into settlement was closed without action (1"The Pink Sheet" Sept. 3, 2001, p. 20)...